Should We Consider Deep Brain Stimulation Discontinuation in Late‐Stage Parkinson's Disease?
Authors:
- Margherita FabbriMFMargherita Fabbri
- Maurizio ZibettiMZMaurizio Zibetti
- Mario Giorgio RizzoneMRMario Giorgio Rizzone
- Giulia GianniniGGGiulia Giannini
- Linda BorelliniLBLinda Borellini
- Alessandro StefaniASAlessandro Stefani
- Francesco BoveFBFrancesco Bove
- Giovanna Calandra‐BuonauraGCGiovanna Calandra‐Buonaura
- Nicola ModugnoNMNicola Modugno
- Carla PianoCPCarla Piano
- Antonella PeppeAPAntonella Peppe
- 25 May 2020
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 35 (8) , 1379-1387
Abstract
Background: Subthalamic deep brain stimulation (STN‐DBS) effects may decrease with Parkinson's disease (PD) progression. There is no indication if, when, and how to consider the interruption of DBS treatment in late‐stage PD. The objective of the current study was to investigate the percentage of “poor stimulation responders” among late‐stage PD patients for elaborating an algorithm to decide whether and when DBS discontinuation may be considered.Methods: Late‐stage PD patients (Hoehn Yahr stage ≥4 and Schwab and England Scale <50 in medication on/stimulation on condition) treated with STN‐DBS for at least 5 years underwent a crossover, double‐blind, randomized evaluation of acute effects of stimulation. Physicians, caregivers, and patients were blinded to stimulation conditions. Poor stimulation responders (MDS‐UPDRS part III change <10% between stimulation on/medication off and stimulation off/medication off) maintained the stimulation off/medication on condition for 1 month for open‐label assessment.Results: Thirty‐six patients were included. The acute effect of stimulation was significant (17% MDS‐UPDRS part III), with 80% of patients classified as “good responders.” Seven patients were classified as “poor stimulation responders,” and the stimulation was switched off, but in 4 cases the stimulation was switched back “on” because of worsening of parkinsonism and dysphagia with a variable time delay (up to 10 days). No serious adverse effects occurred.Conclusions: The vast majority of late‐stage PD patients (92%) show a meaningful response to STN‐DBS. Effects of stimulation may take days to disappear after its discontinuation. We present a safe and effective decisional algorithm that could guide physicians and caregivers in making challenging therapeutic decisions in late‐stage PD. © 2020 International Parkinson and Movement Disorder SocietyKeywords
This publication has 34 references indexed in Scilit:
- Deep Brain Stimulation in Movement Disorders: From Experimental Surgery to Evidence‐Based TherapyMovement Disorders, 2019
- Long-term outcomes of deep brain stimulation in Parkinson diseaseNature Reviews Neurology, 2019
- Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approachCurrent Medical Research and Opinion, 2018
- Does deep brain stimulation of the subthalamic nucleus prolong survival in Parkinson's Disease?Movement Disorders, 2018
- MDS clinical diagnostic criteria for Parkinson's diseaseMovement Disorders, 2015
- Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patientsBrain, 2011
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Late-stage Parkinson’s disease: the Barcelona and Lisbon cohortJournal of Neurology, 2010
- Relationships between age and late progression of Parkinson's disease: a clinico-pathological studyBrain, 2010
- Deep brain stimulation: Preoperative issuesMovement Disorders, 2006